Table 1.
Test schemes covered under MPQAP EQAS program for solid tumors.
Table 2.
Summary of precautionary measures to be taken for dealing with patients and diagnostic samples.
Fig 1.
Responses from 15 participants who took part in the survey (A)Participants involved in COVID-19 testing (B) Issues faced by participants in procuring COVID-19 consumables.
Fig 2.
Survey response data from various participating centres depicting the impact of pandemic on routine diagnostics (A)Effect on kits, consumables and manpower (B) Effect on volume of test requisitions (C) Effect on revenue generated from diagnostics (D) Effect on work profile and pay (E) Effect on Turn-around time (TAT) for testing and discontinuation of tests (F) Response for participation in EQAS scheme.
Fig 3.
Response to survey conducted on use of alternative quality measures followed by participant laboratories.
Fig 4.
Performance of all participants who participated in the FISH-Her2/neu module.
Fig 5.
Trend of different methods of pre-treatment, enzymes used, probe used along with hybridization buffer and image analysis software employed by participants for the FISH-HER2/neu module.
Fig 6.
Performance of participants who participated in Digi EQAS module for RAS and BRAF mutations.
Fig 7.
Effect of pandemic on number of days required to submit the test results before and during pandemic.